E-Z-EM, Inc. Announces Completion of Merger

  
    
  
  
    
      E-Z-EM, Inc. (NASDAQ: EZEM) announced today it had completed the merger 
      of Eagle Acquisition Sub, Inc., a wholly owned subsidiary of Bracco 
      Diagnostics, Inc. (Bracco), the US-based subsidiary of Bracco Imaging 
      S.p.A and part of the Bracco Group, with and into E-Z-EM, and the other 
      transactions contemplated by the Agreement and Plan of Merger, dated as 
      of October 30, 2007, among Bracco, Eagle Acquisition, E-Z-EM and, for 
      the limited purposes specified therein, Bracco Imaging. Under the terms 
      of the merger agreement, each outstanding common share of E-Z-EM was 
      converted into the right to receive $21.00 in cash, without interest and 
      less any required withholding tax. E-Z-EM is now a wholly owned 
      subsidiary of Bracco.
    
    
      About E-Z-EM, Inc.
    
    
      E-Z-EM is a leading manufacturer of contrast agents for gastrointestinal 
      radiology. The Company is the developer of VoLumen®, 
      a patent-pending, next generation low density barium sulfate suspension 
      for use as an oral contrast in Multidetector CT (MDCT) and Positron 
      Emission Tomography (PET/CT) studies. The Company also offers Empower®, 
      the first family of CT injectors on the market with patented EDA™ 
      technology that can help detect contrast extravasation, and offers a 
      complete product set for the virtual colonoscopy practitioner. This 
      product line consists of virtual colonoscopy hardware, software, 
      nutritional prep kits and bowel cleaners, tagging agents and a carbon 
      dioxide colon insufflation system. The Company is also the exclusive 
      world-wide manufacturer and marketer of RSDL for military services and 
      first-responder organizations. RSDL is a patented, broad-spectrum liquid 
      chemical warfare agent decontaminant, that neutralizes or removes 
      chemical agents from skin on contact, leaving a non-toxic residue that 
      can be rinsed off with water.
    
    
      About the Bracco Group
    
    
      Bracco Imaging S.p.A is one of the world leading companies in the 
      imaging agent business, with products sold in over 80 countries. Bracco 
      Diagnostics, Inc. is the U.S. subsidiary of Bracco Imaging which is 
      headquartered in Milan, Italy.
    
    
      Bracco Imaging is a subsidiary of Bracco S.p.A, holding company of the 
      Bracco Group, which also markets Ethical and OTC pharmaceutical products 
      in Italy as well as Advanced Medical Technology systems on a world wide 
      basis. Furthermore, the Bracco Group offers diagnosis services through 
      the Milan-based Centro Diagnostico Italiano (Italian Diagnostic Center).
    
    
      Forward Looking Statements
    
    
      The statements made in this document contain certain forward-looking 
      statements. Words such as "expects," "intends," "anticipates," "plans," 
      "believes," "seeks," "estimates" or variations of such words and similar 
      expressions, are intended to identify such forward-looking statements. 
      The forward-looking statements contained in this release may involve 
      numerous risks and uncertainties, known and unknown, beyond E-Z-EM’s 
      control. Such risks and uncertainties may include: the ability of E-Z-EM 
      to develop its products, unexpected costs or liabilities resulting from 
      the merger transaction, price increases of raw materials and components, 
      foreign currency exchange rate fluctuations as well as the risk factors 
      listed from time to time in the SEC filings of E-Z-EM, Inc., including 
      but not limited to its Annual Report on Form 10-K for the fiscal year 
      ended June 2, 2007 and its Form 10-Q for the quarter ended December 1, 
      2007. Consequently, actual future results may differ materially from the 
      anticipated results expressed in the forward-looking statements, and 
      investors are cautioned not to place undue reliance on the 
      forward-looking statements included in this release.